In vivo research plays a pivotal role in the development of innovative therapeutics, particularly biologics. As researchers and drug developers continue to explore new targets and refine existing therapies, high-quality research tools like Benchmark Positive Antibodies are essential. These anti-human antibodies, specifically designed for in vivo applications, act like biosimilars to help researchers investigate antibody drugs.
What Are Anti-Human Antibodies?
Anti-human antibodies are antibodies that specifically bind to human antigens, typically proteins found on the surface of human cells. These antibodies can be used in a variety of applications, from diagnostic assays to therapeutic development, but are particularly valuable in in vivo research, where their interaction with human targets in living organisms (often animal models) can provide critical insights into how a human-targeted drug might behave in clinical settings.
In the context of in vivo studies, anti-human antibodies like those offered for Benchmark Positive Antibodies enable researchers to simulate human-target interactions within animal models. By acting like biosimilars, these benchmark positive antibodies can be substitutes for the antibody drug.
The Role of Benchmark Positive Antibodies in Drug Research
The development of innovative drugs is heavily dependent on the identification of viable drug targets—proteins or pathways that, when modulated, result in a therapeutic effect. However, suitable drug targets are still limited, and competition is fierce. Researchers must decide whether to follow popular, well-validated targets or to pioneer new, uncharted ones. In either case, the need for reliable and high-quality research tools remains critical.
Abinvivo’s Benchmark Positive Antibodies address this with a variety of anti-human antibodies that are specifically tailored for key drug targets. These include:
PD-1 (Programmed Death-1): A checkpoint protein that plays a crucial role in inhibiting immune responses, PD-1 is a major target for immunotherapy, especially in cancer treatment. Anti-PD-1 antibodies are used to study immune checkpoint blockade, a strategy that releases the immune system’s brakes, allowing it to attack cancer cells.
CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4): Another checkpoint inhibitor, CTLA-4 modulates immune responses, and anti-CTLA-4 antibodies have been instrumental in developing therapies like ipilimumab for cancer treatment.
HER2 and HER3: These proteins are part of the human epidermal growth factor receptor (HER) family and are important targets in breast cancer and other malignancies. Anti-HER2 antibodies, for example, have been crucial in the development of drugs like trastuzumab, which targets HER2-positive cancers.
4-1BB (CD137): This protein is a member of the TNF receptor family and is an important target in cancer immunotherapy, as it plays a role in activating T-cells and promoting an anti-tumor immune response.
Related: Cell Signaling Pathways
Biointron’s catalog products for in vivo research can be found at Abinvivo, where we have a wide range of Benchmark Positive Antibodies, Isotype Negative Antibodies, Anti-Mouse Antibodies, Bispecific Antibodies, and Antibody-Drug Conjugates. Contact us to find out more at info@biointron.com or +86 400-828-8830 / +1(732)790-8340.
